Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: April 15, 2009
Last updated: May 5, 2014
Last verified: May 2014
This study will provide treatment with Tarceva to patients with advanced NSCLC who have received >=1 course of standard chemotherapy or radiation therapy, or who are not medically suitable for either. Efficacy and safety will be monitored throughout the study. The anticipated time on study treatment is as long as the patient is, in the investigator's opinion, benefiting from the therapy and the target sample size is 500+ individuals.

Condition Intervention Phase
Non-Small Cell Lung Cancer
Drug: erlotinib [Tarceva]
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Expanded-access Study of the Effect of Tarceva on Treatment Response in Patients With Advanced Stage IIIB/IV Non-small-cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety:Adverse events, serious adverse events, premature withdrawals\n\n [ Time Frame: At each clinic visit, throughout study.Length of study not specified ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy: Response rate, time to progression, survival [ Time Frame: At each clinic visit, throughout study. length of study not specified ] [ Designated as safety issue: No ]

Enrollment: 7040
Study Start Date: November 2004
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: erlotinib [Tarceva]


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients >=18 years of age;
  • histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent NSCLC;
  • previous treatment with <=2 prior chemotherapy regimens.

Exclusion Criteria:

  • previous systemic anti-cancer therapy with HER1/EGFR inhibitors;
  • inability to take oral medication;
  • any other malignancies within 5 years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00949910

  Show 544 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Study Chair: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT00949910     History of Changes
Other Study ID Numbers: MO18109 
Study First Received: April 15, 2009
Last Updated: May 5, 2014
Health Authority: Netherlands:Medicines Evaluation Board

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 23, 2016